Zeltia: Report at 31 December 2005

Madrid (ots/PRNewswire) - Group:

- Capital increase at Zeltia. The placement of 10.75 million new shares among qualified international investors raised 65 million euro

- R&D expenditure up 24%

- Net revenues in 2005: 72 million euro

- Net cash position at 31 December 2005: 93 million euro net of short-term financial debt and 51 million euro net of total financial debt

PharmaMar:

- Yondelis(R):

- Phase III pivotal trial on ovarian cancer commenced

- Recruitment for the pivotal randomised trial on soft-tissue sarcoma was completed

- Aplidin(R):

- Phase II studies on prostate and bladder cancer commenced

- Combination studies with other chemotherapy agents commenced

- Zalypsis(R), PharmaMar's fifth compound to reach clinical trials

- PM02734 is PharmaMar's sixth compound to reach clinical
trials

Xylazel:

- Launched a full range of Xylazel-brand wood protecting paints and varnishes.

- Conclusion of licensing and marketing agreement with ICI.

Isabel Lozano
Chief Executive Officer
PHARMAMAR, S.A.
C/ Reyes, 1.
Colmenar Viejo Madrid
Telephone +34-91-846-60-00
Catherine Moukheibir
Head of Capital Market Strategy
ZELTIA, S.A.
José Abascal, 2. Madrid
Telephone +34-91-444-45-00
Ma Luisa de Francia
Chief Financial Officer
ZELTIA, S.A.
José Abascal, 2. Madrid
Telephone +34-91-444-45-00

For a copy of the full results, please refer to www.zeltia.com

Rückfragen & Kontakt:

Isabel Lozano, Chief Executive Officer, PHARMAMAR, S.A., C/ Reyes,
1., Colmenar Viejo, Madrid, Telephone +34-91-846-60-00; Catherine
Moukheibir, Head of Capital Market Strategy, ZELTIA, S.A., José
Abascal, 2. Madrid, Telephone +34-91-444-45-00; Ma Luisa de Francia,
Chief Financial Officer, ZELTIA, S.A., José Abascal, 2. Madrid,
Telephone +34-91-444-45-00

OTS-ORIGINALTEXT UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | PRN0003